Dual Trigger Compared with Human Chorionic Gonadotropin Alone and Effects on Clinical Outcome of Intracytoplasmic Sperm Injection

Document Type : Original Article

Authors

1 Department of Obstetrics and Gynaecology, Koc University Hospital, Istanbul, Turkey 2. Isfahan Fertility and Infertility Centre, Isfahan, Iran

2 Department of Obstetrics and Gynaecology, Koc University Hospital, Istanbul, Turkey

3 Department of Obstetrics and Gynaecology, Koc University Hospital, Istanbul, Turkey Department of Obstetrics and Gynaecology, Koc University, Faculty of Medicine, Istanbul, Turkey

Abstract

Background: This study compared outcomes of the standard 6000 IU human chorionic gonadotropin (hCG) trigger
with a dual trigger comprised of 6000 IU hCG and 1 mg leuprolide acetate for final oocyte maturation in an intracytoplasmic sperm injection (ICSI) cycle. By convention, ICSI was performed in most cases at the clinic.
Materials and Methods: In this retrospective study, a total of 50 women were included in each arm. Participants
were matched for age, indication and number of prior assisted reproduction technology (ART) cycles. Women at risk
for ovarian hyperstimulation syndrome (OHSS) were excluded. A flexible gonadotropin releasing hormone (GnRH)
antagonist protocol was used and final oocyte maturation was triggered when two leading follicles were >17 mm.
Distribution of variables was evaluated visually with histograms. Continuous variables were defined by mean (standard
deviation) or median (25th-75th percentile) depending on distribution characteristics. Categorical variables were
defined by numbers and percentages. Continuous variables were compared between the groups with the t test or
Mann-Whitney U test as appropriate. Categorical variables were compared by the chi-square test and its derivatives
as appropriate. A two-sided P<0.05 indicated statistical significance.
Results: Both groups had similar antral follicle counts, median parity (0) and number of previous failed cycles (0).
The median number of oocytes (8 vs. 7), metaphase-two oocytes (6 vs. 5.5), blastocysts (1 vs. 1), clinical pregnancy
rates (CPR) (28% vs. 22%), ongoing pregnancy rates (OPR) (22% vs. 20%) and pregnancy rate per transfer (53.3%
vs 53.8%) were similar between the dual trigger and hCG only groups, respectively.
Conclusion: Dual trigger for oocyte maturation stimulation failed to improve the ICSI outcome.

Keywords


  1. Abbara A, Clarke SA, Dhillo WS. Novel Concepts for inducing final oocyte maturation in in vitro fertilization treatment. Endocr Rev. 2018; 39(5): 593-628.
  2. Du DF, Li MF, Li XL. Ovarian hyperstimulation syndrome: a clinical retrospective study on 565 inpatients. Gynecol Endocrinol. 2020; 36(4): 313-317.
  3. Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz- Eldor J, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab. 2002; 87(2): 709-715.
  4. Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab. 1990; 71(4): 918-922.
  5. Imoedemhe DA, Chan RC, Sigue AB, Pacpaco EL, Olazo AB. A new approach to the management of patients at risk of ovarian hyperstimulation in an in-vitro fertilization programme. Hum Reprod. 1991; 6(8): 1088-1091.
  6. Segal S, Casper RF. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization. Fertil Steril. 1992; 57(6): 1254- 1258.
  7. Alyasin A, Mehdinejadiani Sh, Ghasemi M. GnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: a review article. Int J Reprod Biomed. 2016; 14(9): 557-566.
  8. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2006; 12(2): 159-168.
  9. Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grondahl ML, Westergaard L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005; 20(5): 1213-1220.
  10. Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005; 20(10): 2887-2892.
  11. Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod. 2013; 28(9): 2522-2528.
  12. Ben-Haroush A, Sapir O, Salman L, Altman E, Garor R, Margalit T, et al. Does ‘dual trigger’ increase oocyte maturation rate? J Obstet Gynaecol. 2020; 40(6): 860-862.
  13. Borgbo T, Povlsen BB, Andersen CY, Borup R, Humaidan P, Grondahl ML. Comparison of gene expression profiles in granulosa and cumulus cells after ovulation induction with either human chorionic gonadotropin or a gonadotropin-releasing hormone agonist trigger. Fertil Steril. 2013; 100(4): 994-1001.
  14. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Thomas S. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertil Steril. 2008; 90(1): 231-233.
  15. Andersen Y. Effect of FSH and its different isoforms on maturation of oocytes from pre-ovulatory follicles. Reprod Biomed Online. 2002; 5(3): 232-239.
  16. Haas J, Zilberberg E, Nahum R, Sason AM, Hourvitz A, Gat I, et al. Does double trigger (GnRH-agonist + hCG) improve outcome in poor responders undergoing IVF-ET cycle? A pilot study. Gynecol Endocrinol. 2019; 35(7): 628-630.
  17. Lin MH, Wu FSY, Hwu YM, Lee RKK, Li RS, Li SH. Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve. Reprod Biol Endocrinol. 2019; 17(1): 7.
  18. Decleer W, Osmanagaoglu K, Seynhave B, Kolibianakis S, Tarlatzis B, Devroey P. Comparison of hCG triggering versus hCG in combination with a GnRH agonist: a prospective randomized controlled trial. Facts Views Vis Obgyn. 2014; 6(4): 203-209.
  19. Glujovsky D, Farquhar C, Quinteiro Retamar AM, Alvarez Sedo CR, Blake D. Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology. Cochrane Database Syst Rev. 2016; (6): Cd002118.
  20. Graham J, Han T, Porter R, Levy M, Stillman R, Tucker MJ. Day 3 morphology is a poor predictor of blastocyst quality in extended culture. Fertil Steril. 2000; 74(3): 495-497.
  21. Milki AA, Hinckley MD, Gebhardt J, Dasig D, Westphal LM, Behr B. Accuracy of day 3 criteria for selecting the best embryos. Fertil Steril. 2002; 77(6): 1191-1195.
  22. Eftekhar M, Farid Mojtahedi M, Miraj S, Omid M. Final follicular maturation by administration of GnRH agonist plus HCG versus HCG in normal responders in ART cycles: an RCT. Int J Reprod Biomed. 2017; 15(7): 429-434.
  23. Kim CH, Ahn JW, You RM, Kim SH, Chae HD, Kang BM. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization. J Reprod Med. 2014; 59(1-2): 63-68.
  24. Ding N, Liu X, Jian Q, Liang Z, Wang F. Dual trigger of final oocyte maturation with a combination of GnRH agonist and hCG versus a hCG alone trigger in GnRH antagonist cycle for in vitro fertilization: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2017; 218: 92-98.
  1. Lin MH, Wu FSY, Lee RKK, Li SH, Lin SY, Hwu YM. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles. Fertil Steril. 2013; 100(5): 1296-1302.
  2. Schachter M, Friedler S, Ron-El R, Zimmerman AL, Strassburger D, Bern O, Raziel A. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study. Fertil Steril. 2008; 90(4): 1087-1093.
  3. Fabris AM, Cruz M, Legidos V, Iglesias C, Munoz M, Garcia-Velasco JA. Dual triggering with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin in patients with a high immature oocyte rate. Reprod Sci. 2017; 24(8): 1221-1225.
  4. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol. 2005; 34(1): 215-220.
  5. Morton V, Torgerson DJ. Regression to the mean: treatment effect without the intervention. J Eval Clin Pract. 2005; 11(1): 59-65.
  6. Griffin D, Feinn R, Engmann L, Nulsen J, Budinetz T, Benadiva C. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates. Fertil Steril. 2014; 102(2): 405-409.
  7. Zhang J, Wang Y, Mao X, Chen Q, Hong Q, Cai R, et al. Dual trigger of final oocyte maturation in poor ovarian responders undergoing IVF/ICSI cycles. Reprod Biomed Online. 2017; 35(6): 701-707.
  8. Lamb JD, Shen S, McCulloch C, Jalalian L, Cedars MI, Rosen MP. Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. Fertil Steril. 2011; 95(5): 1655-1660.
  9. Mourad S, Brown J, Farquhar C. Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017; 1(1): CD012103.